Frederick A Spencer1, Jerry H Gurwitz2, Sam Schulman3, Lori-Ann Linkins3, Mark A Crowther3, Jeffrey S Ginsberg3, Agnes Y Y Lee4, Jane S Saczynski5, Sonia Anand3, Darleen Lessard6, Cathy Emery7, Wei Huang8, Robert J Goldberg6. 1. Department of Medicine, McMaster University Medical Center, Hamilton, Ontario, Canada; Department of Medicine, University of Massachusetts Medical School, Worcester. Electronic address: fspence@mcmaster.ca. 2. Department of Medicine, University of Massachusetts Medical School, Worcester; Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Reliant Medical Group, and Fallon Community Health Plan, Worcester. 3. Department of Medicine, McMaster University Medical Center, Hamilton, Ontario, Canada. 4. Department of Medicine, Vancouver General Hospital, British Columbia, Canada. 5. Department of Medicine, University of Massachusetts Medical School, Worcester; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester. 6. Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester. 7. Department of Medicine, University of Massachusetts Medical School, Worcester. 8. Department of Surgery, University of Massachusetts Medical School, Worcester.
Abstract
BACKGROUND: While the incidence of venous thromboembolism increases with age, little is known about its contemporary management or outcomes in older patients. Our goal was to compare the characteristics, treatment, and outcomes associated with venous thromboembolism, in patients aged 65-69 years, 70-74 years, 75-79 years, and 80+ years. METHODS/PARTICIPANTS: We prospectively followed 542 subjects aged ≥65 years with venous thromboembolism from January 2008 through August 2011 at 6 sites. In addition, a retrospective study of 681 additional subjects aged ≥65 years with venous thromboembolism diagnosed in 2007 and 2009 was conducted at the same 6 sites. RESULTS: With advancing age, patients were more likely to suffer provoked venous thromboembolism but less likely to present with pulmonary embolism. Patients with unprovoked, provoked, or malignancy-associated venous thromboembolism received warfarin for a median of 401 days, 203 days, and 529 days, respectively. Age ≥80 years was not associated with an increased risk of recurrent venous thromboembolism, but there was an increased risk of all-cause mortality. CONCLUSION: With advancing age, patients are more likely to suffer hospital-associated and provoked venous thromboembolism. Many elderly patients with provoked or unprovoked venous thromboembolism were treated for >3 months or >12 months, respectively. Given that advanced age was not associated with increased risk of recurrent venous thromboembolism, but elderly patients in general have a higher risk of bleeding from continued anticoagulant therapy, such practice is potentially harmful. At the same time, such an argument could be used to more vigorously offer prophylaxis in the first place.
BACKGROUND: While the incidence of venous thromboembolism increases with age, little is known about its contemporary management or outcomes in older patients. Our goal was to compare the characteristics, treatment, and outcomes associated with venous thromboembolism, in patients aged 65-69 years, 70-74 years, 75-79 years, and 80+ years. METHODS/PARTICIPANTS: We prospectively followed 542 subjects aged ≥65 years with venous thromboembolism from January 2008 through August 2011 at 6 sites. In addition, a retrospective study of 681 additional subjects aged ≥65 years with venous thromboembolism diagnosed in 2007 and 2009 was conducted at the same 6 sites. RESULTS: With advancing age, patients were more likely to suffer provoked venous thromboembolism but less likely to present with pulmonary embolism. Patients with unprovoked, provoked, or malignancy-associated venous thromboembolism received warfarin for a median of 401 days, 203 days, and 529 days, respectively. Age ≥80 years was not associated with an increased risk of recurrent venous thromboembolism, but there was an increased risk of all-cause mortality. CONCLUSION: With advancing age, patients are more likely to suffer hospital-associated and provoked venous thromboembolism. Many elderly patients with provoked or unprovoked venous thromboembolism were treated for >3 months or >12 months, respectively. Given that advanced age was not associated with increased risk of recurrent venous thromboembolism, but elderly patients in general have a higher risk of bleeding from continued anticoagulant therapy, such practice is potentially harmful. At the same time, such an argument could be used to more vigorously offer prophylaxis in the first place.
Authors: Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch Journal: Blood Adv Date: 2018-11-27
Authors: Wei Huang; Robert J Goldberg; Frederick A Anderson; Alexander T Cohen; Frederick A Spencer Journal: J Thromb Thrombolysis Date: 2016-04 Impact factor: 2.300
Authors: Marie Méan; Tobias Tritschler; Andreas Limacher; Stéphane Breault; Nicolas Rodondi; Drahomir Aujesky; Salah D Qanadli Journal: PLoS One Date: 2017-06-08 Impact factor: 3.240
Authors: Annatina Schnegg-Kaufmann; Sara Calzavarini; Andreas Limacher; Marie Mean; Marc Righini; Daniel Staub; Juerg-Hans Beer; Beat Frauchiger; Joseph Osterwalder; Nils Kucher; Christian M Matter; Marc Husmann; Martin Banyai; Markus Aschwanden; Lucia Mazzolai; Oliver Hugli; Michael Nagler; Michael Daskalakis; Nicolas Rodondi; Drahomir Aujesky; Anne Angelillo-Scherrer Journal: J Thromb Haemost Date: 2019-02 Impact factor: 5.824
Authors: Ghazwa B Korayem; Omar A Alshaya; Norah S Alsubaie; Dalal A Alabdulkarim; Omar A Almohammed; Osamah M Alfayez; Majed S Al Yami Journal: Saudi Pharm J Date: 2021-04-28 Impact factor: 4.330